Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Biohaven Ltd.NYSE: BHVN

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue remains negative

Q2 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
BHVN Competitors
Revenue for BHVN and competitors
Company Period LTM YoY 3-year CAGR
IMCRImmunocore Holdings plcLTM Mar 2026$385.76M USD+15.6%+27.3%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$314.85M USD+41.5%+38.3%
ABCLAbCellera Biologics Inc.LTM Sep 2026$67.86M USD+92.1%-46.3%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$66.09M USD+45.0%+9.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$112K USD-95.7%-14.0%
BHVNBiohaven Ltd.LTM Jun 2026$0 USD——
PHVSPharvaris N.V.LTM Sep 2026€0 EUR——
IMNMImmunome, Inc.LTM Sep 2026$0 USD-100.0%—
VERAVera Therapeutics, Inc.LTM Jun 2026$0 USD——
ZBIOZenas BioPharma, Inc.LTM Mar 2026$0 USD-100.0%—
SIONSionna Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding BHVN) —+15.6%+9.1%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.14M
Gross Profit0000(4.14M)
Gross Margin—————
Research & Development181.49M437.07M373.28M795.87M635.07M
Selling, General & Admin37.41M130.86M62.77M89.24M106.17M
Operating Expenses218.9M567.93M436.05M885.11M741.24M
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
EBITDA(211.04M)(568.46M)(402.64M)(837.83M)(727.46M)
EBITDA Margin—————
Operating Income(218.9M)(567.93M)(436.05M)(885.11M)(745.38M)
Operating Margin—————
Interest Income0017.73M21.33M14.59M
Interest Expense00000
Other Income / Expenses6.47M(1.91M)26.5M39.42M8M
Income Before Tax(212.43M)(569.84M)(409.55M)(845.69M)(737.38M)
Pre-Tax Margin—————
Income Tax Expense1.37M438K(1.38M)735K1.44M
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Net Margin—————
EPS (Basic)(5.97)(12.75)(5.73)(9.28)(6.86)
EPS (Diluted)(5.97)(12.75)(5.73)(9.28)(6.86)
Weighted Avg Shares35.82M44.74M71.2M91.23M107.62M
Weighted Avg Shares (Diluted)35.82M44.74M71.2M91.23M107.62M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.